{"preliminary_commentary":{"by_channel":{"x_thread":2,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT06162221","nct_id":"NCT06162221","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06162221. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"RMC-6291 (BID), RMC-6236 (QD), and Pembrolizumab (Q3W) with or without Chemotherapy (Q3W)","label":"Subprotocol A: KRAS G12C-Mutated Solid Tumors","type":"EXPERIMENTAL"},{"description":"RMC-6236 (QD) and Pembrolizumab (Q3W) with or without Chemotherapy (Q3W)","label":"Subprotocol B: RAS-mutated NSCLC","type":"EXPERIMENTAL"},{"description":"RMC-9805 (QD or BID), RMC-6236 (QD), and Pembrolizumab (Q3W) with or without Chemotherapy (Q3W).","label":"Subprotocol C: RAS G12D-mutated NSCLC","type":"EXPERIMENTAL"},{"description":"RMC-9805 (QD)","label":"Subprotocol D: RAS G12D-mutated NSCLC","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-12","type":"ESTIMATED"},"conditions":["Non-Small Cell Lung Cancer, NSCLC","KRAS, NRAS, HRAS-mutated NSCLC","KRAS G12C-mutated Solid Tumors, Lung Cancer","Lung Cancer Stage IV, Advanced Solid Tumor, Cancer","RAS G12D-mutated NSCLC"],"enrollment":{"count":616,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"RMC-6291","otherNames":[],"type":"DRUG"},{"name":"RMC-6236","otherNames":[],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":[],"type":"DRUG"},{"name":"Cisplatin","otherNames":[],"type":"DRUG"},{"name":"Carboplatin","otherNames":[],"type":"DRUG"},{"name":"Pemetrexed","otherNames":[],"type":"DRUG"},{"name":"RMC-9805","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-19","lead_sponsor":"Revolution Medicines, Inc.","official_title":"A Platform Study of RAS(ON) Inhibitors in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2027-06","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Adverse events","timeFrame":"Up to 5 years"},{"measure":"Dose limiting toxicities","timeFrame":"21 days"}],"references":[{"citation":"Cregg J, Edwards AV, Chang S, Lee BJ, Knox JE, Tomlinson ACA, Marquez A, Liu Y, Freilich R, Aay N, Wang Y, Jiang L, Jiang J, Wang Z, Flagella M, Wildes D, Smith JAM, Singh M, Wang Z, Gill AL, Koltun ES. Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers. J Med Chem. 2025 Mar 27;68(6):6064-6083. doi: 10.1021/acs.jmedchem.4c02314. Epub 2025 Mar 8.","pmid":"40056080","type":"DERIVED"}],"start_date":{"date":"2024-01-18","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC","url":"https://clinicaltrials.gov/study/NCT06162221"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06162221"}